Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: IXICO plc

Market Cap 19.08M 25.64M 22.1M 20.34M 35.84M 2.42B 36.2M 240M 93.92M 1.19B 96.21M 94.18M 4.11B P/E Ratio 2026 *
-5.47x
P/E Ratio 2027 * -6.73x
Enterprise Value 9.48M 12.74M 10.98M 10.1M 17.81M 1.2B 17.98M 119M 46.66M 590M 47.8M 46.79M 2.04B EV / Sales 2026 *
1.26x
EV / Sales 2027 * 1.49x
Free-Float
89.2%
Yield 2026 *
-
Yield 2027 * -
3 years 0.07
Extreme 0.07
0.2
5 years 0
Extreme 0.003
1.09
10 years 0
Extreme 0.003
1.47
Manager TitleAgeSince
Chief Executive Officer 53 19/08/2024
Director of Finance/CFO 50 21/08/2019
Chief Tech/Sci/R&D Officer - 01/06/2025
Director TitleAgeSince
Chairman 51 -
Director/Board Member 62 05/10/2023
Director/Board Member 50 21/08/2019
Change 5-day change 1-year change 3-year change Capi.($)
-53.33%-.--% - - 25.32M
+0.96%+1.94%-12.97%-13.01% 43.03B
+4.02%+7.26%+294.33%+533.90% 32.71B
-1.69%-2.76%+13.70%-16.14% 30.29B
+1.41%-0.70%-0.53%+28.87% 29.4B
+1.16%+2.10%+14.27%+22.05% 25.08B
+2.40%+6.10% - - 13.54B
+0.03%+2.92%+56.75%+114.15% 13.35B
-1.09%-2.37%+5.07%+5.25% 12.97B
+0.93%-0.70%+107.81%+81.19% 12.11B
Average -4.51%+0.83%+59.80%+94.53% 23.61B
Weighted average by Cap. +1.05%+0.82%+60.10%+102.52%

Financials

2026 *2027 *
Net sales 7.5M 10.08M 8.69M 7.99M 14.09M 953M 14.23M 94.51M 36.92M 466M 37.82M 37.02M 1.61B 9M 12.09M 10.42M 9.59M 16.91M 1.14B 17.07M 113M 44.3M 560M 45.39M 44.42M 1.94B
Net income -2.4M -3.23M -2.78M -2.56M -4.51M -305M -4.55M -30.24M -11.81M -149M -12.1M -11.85M -517M -2.8M -3.76M -3.24M -2.98M -5.26M -356M -5.31M -35.29M -13.78M -174M -14.12M -13.82M -603M
Net Debt -9.6M -12.9M -11.12M -10.23M -18.03M -1.22B -18.21M -121M -47.26M -597M -48.41M -47.39M -2.07B -5.7M -7.66M -6.6M -6.08M -10.71M -724M -10.81M -71.83M -28.06M -355M -28.74M -28.14M -1.23B
Logo IXICO plc
IXICO plc is engaged in neuroscience imaging and biomarker analytics, using its artificial intelligence (AI)-driven platform to help advance drug development in neurological disorders. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Alzheimer's disease, Parkinson's disease and Huntington's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include imaging biomarkers, trial management, data analytics, consultancy and post-marketing surveillance. Its TrialTracker platform provides a standardized, compliant and efficient workflow for capturing visual read results of MRI, SPECT, PET and CT scans, supporting single, over-read and double adjudicated read paradigms.
Employees
79
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0865GBP
Average target price
0.2600GBP
Spread / Average Target
+200.58%

Annual profits - Rate of surprise

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!